Drug General Information (ID: DDIG6WUQDH)
Drug Name			Iodide I-123		Drug Info		Sodium iodide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Diagnostic Radiopharmaceuticals				Antithyroid Agents
Structure

Mechanism of Iodide I-123-Sodium iodide Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Iodide I-123				Sodium iodide
Mechanism		Radioiodide				Interfere with the therapeutic effect and/or diagnostic result of radioiodides
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Iodide I-123 when combined with Sodium iodide

Recommended Action
Management		Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Sodium Iodide I-123 (sodium iodide I-123). GE Healthcare, Princeton, NJ.
3	Product Information. Visipaque (iodixanol). Nycomed Inc, Princeton, NJ.